한글목차

2024년에는 GlobalData의 역학 예측이 적용되는 16개국에서 41만 건 이상의 EC 발병이 진단될 것으로 예상됩니다.

화학요법은 진행성 또는 전이성 EC 환자 치료의 근간을 이루며, 전 세계적으로 22개의 혁신적인 EC 치료제가 출시되어 있습니다.

EC의 파이프라인에는 모든 개발 단계에 있는 571개의 분자가 있습니다. 등록 전 단계는 2개의 분자로 구성되어 있으며, 3상 파이프라인에는 22개의 약물이 포함되어 있습니다.

지난 10년간 진행된 1,753건의 임상시험 중 8.61%가 임상 3상 시험인 반면, 43.29%는 임상 2상(임상 2상/III상 포함)이었습니다.

지난 10년간 모든 지역에서 파트너십을 통한 거래가 주류를 이루었으며, 북미는 47.4%, 유럽은 44.1%, 아시아태평양은 39.8%가 파트너십을 통한 거래로 나타났습니다.

이 보고서는 세계 식도암 시장을 조사 분석하여 질병 현황, 시판 중인 약물 및 파이프라인 의약품 평가, 현재와 미래경쟁 구도 등을 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질환 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약품 평가

• 주요 출시 약품
• 개요 : 작용기전별
• 개요 : 분자 유형별
• 제품 개요와 판매 예측

제5장 가격 결정과 상환 평가

• 연간 치료비
• 가격 결정과 상환까지 시간

제6장 파이프라인 의약품 평가

• 중기부터 후기 파이프라인 의약품
• 개요 : 개발 단계별
• 개요 : 작용기전별
• 개요 : 분자 유형별
• 약품 고유 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
• 치료 영역과 적응증 고유의 PTSR 및 LoA

제7장 임상시험 평가

• 과거 개요
• 개요 : 단계별
• 개요 : 현황별
• 개요 : 단계별(진행중/계획된 임상시험)
• 가상 컴포넌트에 의한 시험
• 임상시험 개요 : 지역별
• 단일국/다국간 시험 : 지역별
• 스폰서 주요 20개사와 내역 : 단계별
• 스폰서 주요 20개사와 내역 : 현황별
• 개요 : 엔드포인트 현황별
• 개요 : 인종/민족별
• 등록 데이터
• 임상시험 시설 주요 20개국
• 세계의 주요 20개 시설
• 실현 가능성 분석 - 지역 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

• 합병, 인수, 전략적 제휴 : 지역별
• 최근 합병, 인수, 전략적 제휴

제9장 상업적 평가

• 주요 시장 기업

제10장 향후 시장 촉매

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Esophageal Cancer therapeutics.

In 2024, more than 410,000 diagnosed incident cases of EC are anticipated in the 16 countries covered in GlobalData's epidemiology forecast.

Chemotherapy forms the backbone of therapy in patients with advanced or metastatic EC. There are 22 innovator drugs marketed for EC across geographies.

The EC pipeline has 571 molecules across all stages of development. The pre-registration phase consists of two molecules, whereas the Phase III pipeline contains 22 drugs.

Of the 1,753 trials conducted in the past 10 years, 8.61% were Phase III trials, whereas 43.29% were Phase II trials (including Phase II/III trials).

Over the past decade, partnerships were the predominant deal type in all regions: for North America, Europe, and Asia-Pacific, partnerships were 47.4%, 44.1%, and 39.8% of deals.

Scope

GlobalData's Esophageal Cancer: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Esophageal Cancer market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Esophageal Cancer market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer